Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study
- 1 April 2018
- journal article
- conference paper
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S105-S106